GALAPAGOS
GALAPAGOS NV, commonly referred to as Galapagos, is a pioneering biotechnology company headquartered in the United States, with significant operations in Europe. Founded in 1999, Galapagos has established itself in the pharmaceutical industry, focusing on the discovery and development of innovative medicines for various diseases, including inflammatory and fibrotic conditions. The company is renowned for its unique drug discovery platform, which leverages advanced technologies to identify and develop novel therapeutic candidates. Notable achievements include the successful development of several clinical-stage programmes, positioning Galapagos as a leader in the biopharmaceutical sector. With a commitment to scientific excellence and a robust pipeline, Galapagos continues to make significant strides in transforming patient care through groundbreaking therapies.
DitchCarbon Score
How does GALAPAGOS's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
GALAPAGOS's score of 38 is higher than 63% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
GALAPAGOS's reported carbon emissions
In 2023, GALAPAGOS reported total carbon emissions of approximately 39,632,000 kg CO2e. This figure includes Scope 1 emissions of about 2,922,000 kg CO2e, Scope 2 emissions of approximately 1,132,000 kg CO2e, and a significant contribution from Scope 3 emissions, which totalled around 36,537,000 kg CO2e. Comparatively, in 2022, GALAPAGOS's total emissions were about 58,006,000 kg CO2e, with Scope 1 emissions at approximately 3,180,000 kg CO2e, Scope 2 emissions at around 849,000 kg CO2e, and Scope 3 emissions reaching about 54,609,000 kg CO2e. This indicates a notable reduction in total emissions of about 18,374,000 kg CO2e from 2022 to 2023. Despite these reductions, GALAPAGOS has not set specific reduction targets through the Science Based Targets initiative (SBTi) or other formal climate pledges. The emissions data is not cascaded from any parent organisation, and all figures are reported directly from GALAPAGOS NV. Overall, GALAPAGOS is actively monitoring its carbon footprint across all scopes, but further commitments and targets would enhance its climate strategy.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | |
|---|---|---|
| Scope 1 | 3,180,000 | 0,000,000 |
| Scope 2 | 849,000 | 0,000,000 |
| Scope 3 | 54,609,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
GALAPAGOS is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
